In a report released today, Cedric Besnard from Citi maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of £4.00. The company’s shares closed yesterday at p369.60.

In a report released today, Iain Simpson from Barclays maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target of £4.45. The company’s shares closed yesterday at ...

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

(Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share ...

Pfizer reportedly raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon, ending a years-long separation with the company, per Bloomberg and Yahoo ...

Pfizer has completing its full exit from Weybridge-headquartered health firm Haleon. Haleon has agreed to an off-market purchase of 44,155,844 ordinary shares of £0.01 each from Pfizer. The off-market ...

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

NEW YORK - Pfizer Inc. (NYSE:PFE) has announced its intention to sell approximately 662 million ordinary shares in Haleon plc, which represents about 7.3% of Haleon’s issued share capital and ...